DailyDoctor Archive Specialties Get app
Back to the 23 October 2026 edition

Research · 03 of 05

SELECT mediation analysis could not pin semaglutide's cardiovascular benefit on any measured risk factor

Prescribe semaglutide for cardiovascular protection on the SELECT trial criteria, not on expected weight loss.

Design
Mediation analysis of a double-blind, placebo-controlled randomised trial
Population
SELECT participants: adults with cardiovascular disease, BMI ≥27, no diabetes
Primary outcome
Proportion of MACE reduction mediated by 24-month risk-factor changes
Effect
Joint mediation 31.4% (95% CI −30.1 to 143.6); waist 64.0%, hsCRP 42.1%, all wide CIs

SELECT showed that weekly semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and a BMI of 27 or more without diabetes. This analysis asked how much of that benefit could be explained by changes over 24 months in weight, waist, high-sensitivity CRP, HbA1c, lipids, blood pressure, eGFR and albuminuria, using a counterfactual regression method.

Semaglutide improved every one of these. The largest point estimates of mediation were for waist circumference (64%), CRP (42%), HbA1c (29%) and weight (19.5%), but every interval was very wide, and the authors judged the weight and waist estimates unreliable. All mediators together explained an estimated 31.4% (95% CI −30.1 to 143.6).

The honest reading is that the analysis cannot say how semaglutide protects. The benefit in SELECT is real; its mechanism is not established, and it may not depend on the amount of weight a patient loses.

  • The SELECT benefit applies to the trial population — established cardiovascular disease, BMI of 27 or more, no diabetes.
  • Do not judge whether semaglutide is 'working' for cardiovascular protection by weight loss alone.
  • CRP fell with treatment, but this analysis does not show inflammation is the mechanism.
  • Weight loss from semaglutide does not replace statins, antiplatelets or blood pressure control in secondary prevention.

Why it matters

Patients who lose little weight on semaglutide may still be getting the cardiovascular benefit.

Don't overread it

None of the mediation estimates is precise enough to say CRP, waist or weight explains the effect.

The statistics, in plain English

Mediation intervals that run below 0% and above 100% mean the data are consistent with a factor explaining none of the effect or all of it. The point estimates should not be quoted as fractions of the benefit.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

heartfailurestructuralimaginginterventionacscardiometabolicafib

Tomorrow morning, before your first patient

One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app